DGX vs JNJ: fair value comparison
Quest Diagnostics Incorporated and Johnson & Johnson · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, DGX currently sits closer to the top of our discount ranking. DGX carries the stronger quality grade.
| DGX | JNJ | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $237.14 | $275.23 |
| 12-month range | $173.79–$236.22 | $185.08–$271.19 |
| Sector rank | #103 of 113 Healthcare | #110 of 113 Healthcare |
| Quality grade | C | F |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DGX fair value analysis · JNJ fair value analysis